Navigation Links
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
Date:5/22/2008

BETHESDA, Md., May 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that the company will provide an update on the phase 1 clinical trial underway for its BiTE(R) antibody MT103/MEDI-538 at the 10th International Conference on Malignant Lymphomas, taking place June 4-7 in Lugano, Switzerland.

The presentation, entitled, "Anti-CD19 BiTE Antibody MT103 (MEDI-538) Induces Durable Objective Responses in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL). Update from Ongoing Phase I Study MT103-104" will take place during Poster Session I from 8:00am to 6:00pm on June 5th, 2008 in the Marquee Parco Ciani. Meeting abstracts will first be available during the week of the conference.

The 10th International Conference on Malignant Lymphoma gathers 3,000 leading physicians from all over the world: hematologists, clinical oncologists, pathologists and leading researchers involved in the study and treatment of lymphoid neoplasms, including multiple myeloma and CLL.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of kill
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
7. Micromet Announces Changes in Management Team
8. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... By Tara Haelle ... (HealthDay News) -- Teens are more likely to start ... of attention-deficit hyperactivity disorder (ADHD) or conduct disorder, ... to counsel families about the risk of substance use ... William Brinkman, research director at Cincinnati Pediatric Research Group, ...
(Date:12/24/2014)... Angeles, CA (PRWEB) December 24, 2014 ... wreak havoc on those who have an intolerance to ... to diarrhea, gas, bloating, migraine headaches, joint pain and ... gluten free diet plans that deliver safe and ... certain foods that trigger a gluten allergy reaction. These ...
(Date:12/24/2014)... MA (PRWEB) December 24, 2014 Dr. ... Dentists from across the nation gathered with US Marines ... Dinner to raise funds for the Toys for Tots ... hundreds of thousands of new books and audio books ... go to underprivileged children this Christmas. It represents another ...
(Date:12/24/2014)... There’s a lot going on with The ... now in control of the Senate as well as the ... Act. A lawsuit has been brought against President Obama by ... the ACA have resulted in changes to the law without ... will take place to weigh the validity of subsidies provided ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3
... breathing disorders could face depression, says a study.// ... Wisconsin-Madison studied about 1,400 adults (aged 30-60) for up ... did not have breathing problems during sleep, those with ... times more likely to become depressed during the study, ...
... Anna Pou, during her first ever public appearance, since ... with dangerous injections, confirmed that neither she nor// the ... ,The charge labeled against them by the Louisiana ... second-degree murder. The witness account as mentioned in ...
... has revealed that exposure to high pollution levels can increase ... in Japan have found that the risk of stroke from ... ,Currently breathing and heart problems are associated with the ... hourly levels. ,The findings of the study ...
... (FDA) have approved a virus mix in spray form that ... month.// , ,Processed meats after being packaged get ... combination of viruses that kill this bacteria. Food companies can ... ,This virus mix is not effective against E. ...
... poor training is resulting in unnecessary emergency Caesarean births ... week’s British Medical Journal (BMJ) that expert obstetricians can ... UK, the decision whether to try a vaginal birth, ... Caesarean is taken in the delayed second-stage labor by ...
... A House committee on Wednesday passed a bill that will ... from the South and rural states said that// increased spending ... it is spreading. ,"It shouldn't matter where you ... care and therapy," said Rep. Joe Barton, R-Texas, chairman of ...
Cached Medicine News:Health News:Stroke Linked to High Pollution Levels 2Health News:Skilled Obstetricians to avoid unnecessary Caesareans 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge....
Ultra-fine pick shape tips for grasping and manipulating membranes. Stationary distal jaw with black finish for reduced glare....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Medicine Products: